ѱ̿Ǿǰȸ Ʈ
|
|
|
|
|
|
|
|
|
ǰȸ |
WHO ̿Ǿǰǥȭ ȸ(ECBS) ̵
ǰǾǰó 躸DZⱸ(WHO) ̿Ǿǰ ǥȭ о ¼ͷμ ̵ ϰ ִ. WHO Ʒ ̵ ̸, ̿ ǰ ȸ ۼϿ ѱ̿Ǿǰȸ(johs8739@kobia.kr, 02-2088-3382) 9 8() ް
1.
Establishing stability of in vitro diagnostic medical devices |
Stability() ü Ƿ(IVD) þ ȿ ð (interval 1, 2) ϴ ɷ̴. κ IVD ȿ ϴ ð ݰ Ȯϰ ϴ ִ.
IVD ü ̵ ϱ ۼǾ. WHO PQ(ݼ˻) (expectations, 4 ) ϰ ִ. |
|
̵ 1. Ȯ |
ǰ 2. Ȯ |
2.
Human immunodeficiency virus (HIV) rapid diagnostic tests
for professional use and/or self-testing |
IVD ü HIV ż Ʈ(RDTs) WHO PQ ̵ ϱ ۼǾ. WHO PQ ּ Ǿ , ش 䱸 HIV θ ǵ RDTs Ž м(. HIV/syphilis Ž RDT) ϰ ȴ.
HIV-1 HIV-2 Ͽ ϴ IVD Ȯ IVD, ݵ ǰ ڷ 䱸 ٷ ʴ. |
|
̵ 3. Ȯ |
ǰ 4. Ȯ |
|
|
|
|
'17 2 ÷ܹ̿Ǿǰ 㰡 ũ ˸
- : 9 28()~29()
- : Ÿ
- : ӻ , ؼȹ ۼ
α ȮǴ ̴. () |
|
|
|
|
|
|
û |
|
ǰ |
ӻ |
ܰ |
()彺 |
20170818 |
ǰ ?(Clostridium Botulinum Toxin Type A) а ϱ , ߴ, Ȱ, ౺, ϱ, 1 ӻ |
1 |
|
ڹݽڸ
ȸ |
20170818 |
ȯڿ ںƼ + ָ ȿ ϴ II, , ٱ, ȣƮ ӻ |
2 |
ںƼ(RO5514041),
ָ (MPDL3280A) |
Ÿ
Ʈų
ڸ() |
20170818 |
ġ Ұ ༺ Ǵ ̼ 㳶 ˷γ (HA-high) ڿ ýöƾ+Ÿ Ͽ ýöƾ+Ÿ ȭ ˷δϴ(PEGPH20) ָ ýöƾ+Ÿ PEGPH20 lb, , ӻ |
1 |
PEGPH20,
ָ |
̼
ֽȸ |
20170817 |
༺ ȯ ErbB3 ǥ ϴ ΰ Ŭü ISU104 , ༺ ൿ Ư ϱ 1, , 뷮 ӻ |
1 |
ISU104 |
Zﺴ |
20170816 |
Ұ ĵ Ǿ ȯڿ ġ Ϲ缱ġ Durvalumab + Tremelimumab տ ϱ 2 ӻ |
2 |
MEDI4736
Tremelimumab |
ڼ̿ |
20170814 |
Ǵ ٹ߰ ȯڿ ̵/Ÿ տ Ǵ ̵/Ÿ տ ϴ ӻ 2 |
2 |
Vax-DC/MM |
˹̿ |
20170811 |
༺ ȯڿ Ʈۡ ȿ ϱ
ٱ, , ߴ, 2b/3 ӻ衻
2b 豺 , ٱ |
|
Ʈ |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
LYNPARZA
NDA #208558 |
OLAPARIB |
ſ뷮 |
ASTRAZENECA PHARMS |
08/17/2017 |
DRAX EXAMETAZIME
NDA #208870 |
DRAX EXAMETAZIME; |
Ǵ |
JUBILANT DRAXIMAGE |
08/17/2017 |
BESPONSA
BLA #761040 |
INOTUZUMAB OZOGAMICIN |
- |
WYETH PHARMS INC |
08/17/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Ritemvia |
rituximab |
Lymphoma, Non-Hodgkin
Microscopic Polyangiitis
Wegener Granulomatosis |
13/07/2017 |
Blitzima |
rituximab |
Leukemia, Lymphocytic,
Chronic,
B-Cell Lymphoma, Non-Hodgkin |
13/07/2017 |
Maviret |
glecaprevir / pibrentasvir |
Hepatitis C, Chronic |
13/07/2017 |
|
|
|
|
|
|
|
|
Clinical.gov ̱ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03255018 |
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas |
-Non-Hodgkin Lymphoma
-Lymphoma
-Diffuse Large B-Cell Lymphoma
-Gray Zone Lymphoma
-Primary Central Nervious System Lymphoma |
Drug: Pembrolizumab |
-National Cancer Institute (NCI)
-National Institutes of Health Clinical Center (CC) |
Phase 2 |
NCT03251924 |
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors |
-Cancer
-Tumors
-Neoplasm
-Malignancy |
Drug: BMS-986226
Biological: Nivolumab
Biological: Ipilimumab |
Bristol-Myers Squibb |
Phase 1
Phase 2 |
NCT03256136 |
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer |
Lung Cancer |
Drug: Carboplatin
Drug: Nivolumab
Drug: pemetrexed
Drug: Ipilimumab |
-Massachusetts General Hospital
-Bristol-Myers Squibb |
Phase 2 |
NCT03254927 |
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma |
Advanced
Head and Neck Squamous Cell Carcinoma |
Drug: CDX-3379 and cetuximab |
Celldex Therapeutics |
Phase 2 |
|
|
Clinical.gov |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
Nation |
NCT03255382 |
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM? in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy |
Psoriasis |
Drug: risankizumab
Drug: Fumaderm |
AbbVie |
Phase 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|